Cantor Fitzgerald Lifts Earnings Estimates for Prothena

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for shares of Prothena in a research report issued on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now expects that the biotechnology company will post earnings per share of ($3.59) for the year, up from their previous estimate of ($3.61). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Prothena's current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). The firm had revenue of $2.83 million during the quarter, compared to analyst estimates of $8.18 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company's quarterly revenue was up 5500.0% compared to the same quarter last year. During the same quarter last year, the company earned ($1.34) EPS.

A number of other research analysts also recently commented on PRTA. Chardan Capital restated a "buy" rating and issued a $40.00 target price on shares of Prothena in a research note on Friday, May 9th. StockNews.com upgraded Prothena from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. HC Wainwright reduced their price objective on Prothena from $48.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. JMP Securities dropped their target price on Prothena from $80.00 to $78.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Finally, Royal Bank of Canada dropped their target price on Prothena from $24.00 to $20.00 and set a "sector perform" rating for the company in a report on Friday, February 21st. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $51.71.

Prothena Stock Performance

NASDAQ:PRTA traded up $0.08 during trading hours on Wednesday, hitting $7.26. 270,788 shares of the company's stock traded hands, compared to its average volume of 585,336. The firm has a market cap of $390.78 million, a P/E ratio of -3.16 and a beta of 0.11. Prothena has a twelve month low of $6.47 and a twelve month high of $25.42. The stock's fifty day moving average price is $10.34 and its two-hundred day moving average price is $13.21.

Institutional Trading of Prothena

A number of institutional investors have recently modified their holdings of the company. Virtus ETF Advisers LLC lifted its position in shares of Prothena by 19.3% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after buying an additional 833 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Prothena by 4,626.0% in the first quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 5,875 shares during the period. Headlands Technologies LLC grew its position in shares of Prothena by 196.5% in the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 4,858 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Prothena during the 1st quarter worth $126,000. Finally, Teacher Retirement System of Texas bought a new position in Prothena during the 4th quarter worth $145,000. 97.08% of the stock is currently owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.